Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) | Journal of Clinical Oncology
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III...
PURPOSEImmune checkpoint inhibitors (ICIs) achieve sufficient receptor occupancy at much lower than standard approved dose...
ascopubs.org
Neoadjuvant Pembrolizumab In Combination With Docetaxel And Cisplatin In Patients With Resectable, Locally Advanced HNSCC
Frontiers | Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus...
BackgroundHead and neck squamous cell carcinoma (HNSCC) is the most common type of tumor originating from the squamo...
www.frontiersin.org
📊 En 2026 se registrarán 301.884 nuevos casos de cáncer, un 2% más que en 2025.
🩺 Mayor supervivencia y calidad de vida gracias a la investigación.
📰 Informe SEOM-REDECAN 'Las cifras del cáncer en España 2026' ➡️ https://seom.org/images/Las_Cifras_del_Cancer_en_Espanya_2026.pdf
📰 Nota de prensa #DMCáncer26 ➡️
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) | Journal of Clinical Oncology
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III...
PURPOSEImmune checkpoint inhibitors (ICIs) achieve sufficient receptor occupancy at much lower than standard approved dose...
ascopubs.org
Neoadjuvant Pembrolizumab In Combination With Docetaxel And Cisplatin In Patients With Resectable, Locally Advanced HNSCC
Frontiers | Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus...
BackgroundHead and neck squamous cell carcinoma (HNSCC) is the most common type of tumor originating from the squamo...
www.frontiersin.org
📊 En 2026 se registrarán 301.884 nuevos casos de cáncer, un 2% más que en 2025.
🩺 Mayor supervivencia y calidad de vida gracias a la investigación.
📰 Informe SEOM-REDECAN 'Las cifras del cáncer en España 2026' ➡️ https://seom.org/images/Las_Cifras_del_Cancer_en_Espanya_2026.pdf
📰 Nota de prensa #DMCáncer26 ➡️
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) | Journal of Clinical Oncology
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III...
PURPOSEImmune checkpoint inhibitors (ICIs) achieve sufficient receptor occupancy at much lower than standard approved dose...
ascopubs.org
Neoadjuvant Pembrolizumab In Combination With Docetaxel And Cisplatin In Patients With Resectable, Locally Advanced HNSCC
Frontiers | Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus...
BackgroundHead and neck squamous cell carcinoma (HNSCC) is the most common type of tumor originating from the squamo...
www.frontiersin.org
📊 En 2026 se registrarán 301.884 nuevos casos de cáncer, un 2% más que en 2025.
🩺 Mayor supervivencia y calidad de vida gracias a la investigación.
📰 Informe SEOM-REDECAN 'Las cifras del cáncer en España 2026' ➡️ https://seom.org/images/Las_Cifras_del_Cancer_en_Espanya_2026.pdf
📰 Nota de prensa #DMCáncer26 ➡️
TTCC en cifras
Entidades Colaboradoras
